Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
View/ Open
Author
Wiedemeyer, W. Ruprecht
Dunn, Ian F.
Quayle, Steven N.
Zhang, Jianhua
Chheda, Milan G.
Dunn, Gavin P.
Zhuang, Li
Rosenbluh, Joseph
Chen, Shujuan
Xiao, Yonghong
Shapiro, Geoffrey I.
Hahn, William C.
Chin, Lynda
Published Version
https://doi.org/10.1073/pnas.1001613107Metadata
Show full item recordCitation
Wiedemeyer, W. R., I. F. Dunn, S. N. Quayle, J. Zhang, M. G. Chheda, G. P. Dunn, L. Zhuang, et al. 2010. “Pattern of Retinoblastoma Pathway Inactivation Dictates Response to CDK4/6 Inhibition in GBM.” Proceedings of the National Academy of Sciences 107 (25): 11501–6. doi:10.1073/pnas.1001613107.Abstract
Glioblastoma multiforme (GBM) is a fatal primary brain tumor harboring myriad genetic and epigenetic alterations. The recent multidimensional analysis of the GBM genome has provided a more complete view of the landscape of such alterations and their linked pathways. This effort has demonstrated that certain pathways are universally altered, but that the specific genetic events altered within each pathway can vary for each particular patient's tumor. With this atlas of genetic and epigenetic events, it now becomes feasible to assess how the patterns of mutations in a pathway influence response to drugs that are targeting such pathways. This issue is particularly important for GBM because, in contrast to other tumor types, molecularly targeted therapies have failed to alter overall survival substantially. Here, we combined functional genetic screens and comprehensive genomic analyses to identify CDK6 as a GBM oncogene that is required for proliferation and viability in a subset of GBM cell lines and tumors. Using an available small molecule targeting cyclin-dependent kinases (CDKs) 4 and 6, we sought to determine if the specific pattern of retinoblastoma pathway inactivation dictated the response to CDK4/6 inhibitor therapy. We showed that codeletion of CDKN2A and CDKN2C serves as a strong predictor of sensitivity to a selective inhibitor of CDK4/6. Thus, genome-informed drug sensitivity studies identify a subset of GBMs likely to respond to CDK4/6 inhibition. More generally, these observations demonstrate that the integration of genomic, functional and pharmacologic data can be exploited to inform the development of targeted therapy directed against specific cancer pathways.Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41542785
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)